NASDAQ:PRPH - Nasdaq - US74345W1080 - Common Stock - Currency: USD
Taking everything into account, PRPH scores 0 out of 10 in our fundamental rating. PRPH was compared to 193 industry peers in the Pharmaceuticals industry. PRPH may be in some trouble as it scores bad on both profitability and health. PRPH does not seem to be growing, but still is valued expensively.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -106.49% | ||
ROE | -352.98% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.46 | ||
Debt/FCF | N/A | ||
Altman-Z | -3.68 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.03 | ||
Quick Ratio | 0.98 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
0.3261
-0.03 (-9.34%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 2 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.9 | ||
P/tB | 17.3 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -106.49% | ||
ROE | -352.98% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.46 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 0.5% | ||
Cap/Sales | 0.49% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.03 | ||
Quick Ratio | 0.98 | ||
Altman-Z | -3.68 |